Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Ovarian Neoplasms

  Free Subscription


1 Am J Surg
1 Anticancer Drugs
1 BMC Cancer
1 Cancer Lett
4 Clin Cancer Res
3 Gynecol Oncol
2 Hum Pathol
2 Int J Gynaecol Obstet
2 Int J Oncol
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Surg

    The Christmas miracle of 1809: How a "backwoodsman without a diploma to practice" became the father of abdominal surgery.
    Am J Surg. 2019;217:578-589.
    PubMed     Text format    

    Anticancer Drugs

  2. GUO Q, Yang Q, Li J, Liu G, et al
    Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
    Anticancer Drugs. 2019 Nov 15. doi: 10.1097/CAD.0000000000000858.
    PubMed     Text format     Abstract available

    BMC Cancer

  3. MALIK MZ, Chirom K, Ali S, Ishrat R, et al
    Methodology of predicting novel key regulators in ovarian cancer network: a network theoretical approach.
    BMC Cancer. 2019;19:1129.
    PubMed     Text format     Abstract available

    Cancer Lett

  4. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett 415 (20-29)].
    Cancer Lett. 2019 Nov 15. pii: S0304-3835(19)30561.
    PubMed     Text format    

    Clin Cancer Res

  5. PISANIC TR, Cope L, Lin SF, Yen TT, et al
    Methylomic analysis of ovarian cancers identifies tumor-specific alterations readily detectable in early precursor lesions.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1199.
    PubMed     Text format     Abstract available

  6. CHEN GM, Kannan L, Geistlinger L, Kofia V, et al
    Consensus on Molecular Subtypes of High-grade Serous Ovarian Carcinoma.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0784.
    PubMed     Text format     Abstract available

  7. DENIGER DC, Pasetto A, Robbins PF, Gartner JJ, et al
    T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers.
    Clin Cancer Res. 2018 May 31. pii: 1078-0432.CCR-18-0573.
    PubMed     Text format     Abstract available

  8. PULLIAM N, Fang F, Ozes AR, Tang J, et al
    An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0204.
    PubMed     Text format     Abstract available

    Gynecol Oncol

  9. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Learning curve of high-complexity surgery for advanced ovarian cancer.
    Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
    PubMed     Text format     Abstract available

  10. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
    PubMed     Text format    

  11. LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
    Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
    PubMed     Text format     Abstract available

    Hum Pathol

  12. KATO N, Sato Y, Kamataki A, Fukase M, et al
    PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
    Hum Pathol. 2018 Nov 26. pii: S0046-8177(18)30464.
    PubMed     Text format     Abstract available

  13. PATEL V, Kipp B, Schoolmeester JK
    Corded and Hyalinized Mesonephric-like adenocarcinoma of the uterine Corpus: report of a case mimicking Endometrioid carcinoma.
    Hum Pathol. 2018 Aug 30. pii: S0046-8177(18)30334.
    PubMed     Text format     Abstract available

    Int J Gynaecol Obstet

  14. CHONGYUAN Z, Honglan Z, Yue W, Heng C, et al
    Para-aortic lymphadenectomy below inferior mesenteric artery versus renal vessels in stage IIIC epithelial ovarian cancer: A comparison of surgical outcomes.
    Int J Gynaecol Obstet. 2019 Nov 20. doi: 10.1002/ijgo.13061.
    PubMed     Text format     Abstract available

  15. INZANI F, Angelico G, Santoro A, Musarra T, et al
    A new entity in the pathological spectrum of vulvar neoplasms: The first report of a primary endometrioid adenocarcinoma.
    Int J Gynaecol Obstet. 2019 Aug 2. doi: 10.1002/ijgo.12936.
    PubMed     Text format     Abstract available

    Int J Oncol

  16. BAI Y, Li LD, Li J, Chen RF, et al
    A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
    Int J Oncol. 2019 Nov 13. doi: 10.3892/ijo.2019.4911.
    PubMed     Text format     Abstract available

  17. LIU Q, Liu H, Li L, Dong X, et al
    ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
    Int J Oncol. 2019 Nov 14. doi: 10.3892/ijo.2019.4913.
    PubMed     Text format     Abstract available

    PLoS One

  18. TORRES D, Hou X, Bale L, Heinzen EP, et al
    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    PLoS One. 2019;14:e0224564.
    PubMed     Text format     Abstract available

  19. OLIVEIRA DNP, Carlsen AL, Heegaard NHH, Prahm KP, et al
    Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    PLoS One. 2019;14:e0225249.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.